SAN JOSE, Calif. / Apr 15, 2024 / Business Wire / Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced its partnership with the American Nephrology Nurses Association (ANNA) as a member of its new Partnership Advisory Council. This collaboration underscores Outset’s dedication to supporting the nephrology nursing community and improving patient care in the realm of kidney disease.
Leslie Trigg, Chair and CEO of Outset, shared her thoughts on the partnership: “We enthusiastically support ANNA’s goal of empowering and educating nephrology nurses who are essential to delivering high-quality care to patients with kidney disease. This partnership demonstrates our dedication to enhancing patient outcomes and supporting the vital role of the nephrology nurses who care for them.”
ANNA emphasized the importance of collaboration with industry leaders to advance the nephrology nursing field. “Outset Medical’s support, together with our other corporate partners, is important to our mission,” said Michele Kimball, ANNA Executive Director. “Industry participation aids in our ongoing efforts to provide top-tier education, advocacy, and networking opportunities, all of which helps enable our members to excel in delivering high-quality patient care.”
As partners, Outset will strongly support ANNA’s efforts to bring about changes that expand the role of the nephrology nurse both as a supervisor and provider of care, foster changes that will not only attract, but help retain more nurses in the field of kidney patient care, and advocate for policy changes to better support the entire kidney care workforce.
With its membership, Outset will be part of ANNA’s new Partnership Advisory Council, providing insights and feedback on the future of nephrology nursing. Nephrology nurses play a pivotal role in all stages of kidney care, and the demand has grown as the population rapidly ages. Today, more than 35 million people are living with Chronic Kidney Disease (CKD) and more than 800,000 more are living with kidney failure. The population living with CKD continues to grow at the same time the field of nephrology faces a nursing shortage. In fact, by 2030, experts project a shortage of more than 900,000 nurses across all fields of practice. Since 2004, there has been a 5-7% deficit in registered nurses at outpatient dialysis facilities, and in 2018 alone there were 1,750 unfilled nephrology jobs for RNs at just outpatient facilities, not counting inpatient, pre-dialysis outpatient and transplant positions, according to a 2022 study in the American Journal of Kidney Diseases.
About the American Nephrology Nurses Association
The American Nephrology Nurses Association (ANNA) improves members' lives through education, advocacy, networking, and science. Since it was established as a nonprofit organization in 1969, ANNA has been serving members who span the nephrology nursing spectrum. ANNA has a membership of 7,000 registered nurses and other health care professionals at all levels of practice. Members work in such areas as conservative management, peritoneal dialysis, hemodialysis, continuous renal replacement therapies, transplantation, industry, and government/regulatory agencies. ANNA is committed to advancing the nephrology nursing specialty and nurturing every ANNA member. ANNA achieves these goals by providing the highest quality educational products, programs, and services. Our members are leaders who advocate for patients, mentor each other, and lobby legislators, all to inspire excellence.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Last Trade: | US$1.02 |
Daily Change: | 0.01 0.99 |
Daily Volume: | 419,737 |
Market Cap: | US$53.590M |
November 15, 2024 October 23, 2024 August 07, 2024 June 03, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB